Completed PHASE2 INTERVENTIONAL 2-arm NCT00396721

Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy (SIREPNA)

Pilot Trial of Treatment of Poor-Prognosis IgA Nephropathy With Low Exposure to Sirolimus.

Sponsor: Josep m Cruzado

Conditions Glomerulonephritis, IGA IGA Nephropathy Nephropathy, IGA

Interventions ACE inhibitor + statin Sirolimus (study drug)+ACE inhibitor + statin

Updated 5 times since 2017 Last updated: Sep 14, 2011 Started: Jan 31, 2006 Primary completion: Oct 31, 2009 Completion: Feb 28, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Glomerulonephritis, IGA and IGA Nephropathy, this trial is completed. The trial is conducted by Josep m Cruzado and has accumulated 5 data snapshots since 2006. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2006

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Josep m Cruzado
Wyeth is now a wholly owned subsidiary of Pfizer

Data source: Hospital Universitari de Bellvitge

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• L'Hospitalet de Llobregat, Spain